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Rationale: Placebo-controlled clinical trials on COPD are characterized by premature discon-
tinuation. At present, no clear insight into this phenomenon is available.
Objective: To obtain better insight into the phenomenon of premature discontinuation.
Methods: We analyzed the pattern of discontinuation in the UPLIFT-trial.
Measurements and main results: Premature discontinuation was substantial and greater in the
placebo than in the tiotropium group (45 vs. 37%, p< 0.001). Patients discontinuing were charac-
terized bymore severe COPD (p< 0.0001), greater number of pack years (p< 0.002), smaller pre-
bronchodilator and post-bronchodilator FEV1 (p < 0.0001 for both), and worse SGRQ scores
(p < 0.0001). Rates of decline of FEV1 and SGRQ were greater in non-completers (p < 0.0001 for
both). The latter differences increased over time indicating that the evolution of variables in time
was related to trial completion. The risks of exacerbations and hospitalizations were greater in
non-completers. In logistic regression analysis BMI, post-bronchodilator FEV1, male gender and
treatment with tiotropiumwere positively related to trial completion, whereas age, worse SGRQ,
female gender, current smoking and assignment to the placebo group were negatively related.
Conclusion: Assignment to the control group is related to premature discontinuation. Discontinu-
ationwas important and selective in this large trial. Pulmonary function, health-related quality of
life and smoking are the most important other variables related to discontinuation. The evolution
of variables during the trial is also related to discontinuation. Complete follow-up of discontinued
patients may provide better insight into the efficacy of medication in future trials.
ª 2011 Elsevier Ltd. All rights reserved.vision,UniversityHospital,Universityof Leuven,Herestraat 49, 3000Leuven,Belgium.Tel.:þ3216346807.
zleuven.be (M. Decramer).
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During the last decade several large trials examining the
effects of pharmacotherapy on the progression of chronic
obstructive pulmonary disease, COPD, have been perform-
ed.1e8 It has now been clearly demonstrated that in all of
these trials premature discontinuation rates were very high
ranging from 27% to 53% in the longer term studies.9
Moreover, it has become abundantly clear that discontinu-
ation does not occur randomly without pattern. To begin
with, in virtually all of these trials drop-out rates were
substantially greater in the placebo group than in the active
treatment group, ranging from 29 to 53% and from 26 to
43%, respectively. But more importantly in breaking the
“missing completely at random” assumption, patients
dropped-out faster from the placebo group and the patients
discontinuing from the placebo group were generally worse
than those discontinuing from the active treatment group,
both at baseline and during the study.
In recent years, it has been recognized that this prema-
ture discontinuation impacts the statistical analysis and
hence, the observed treatment effects. This phenomenon
underscores the need for an intention-to-treat (ITT)-analysis
which may be viewed as a superior approach compared to
commonly used analyses, such as complete case (CC) anal-
ysis, per protocol analysis or last observation carried forward
(LOCF). Standard likelihood methods and Bayesian infer-
ences are valid under “missingness at random” (MAR), which
refers to the situation under which missingness is allowed to
depend on observed outcomes and covariates but not further
on unobserved outcomes. Note that MAR contains “missig-
ness completely at random” (MCAR) as a special case. MCAR
implies that missingness can depend on covariates but not on
outcomes, whether observed or not. As such, it is a stronger
condition than MAR. MCAR is required for CC to hold. Even
under MCAR, is LOCF not necessarily valid, as it requires
a different and highly unrealistic set of conditions to hold
(such as the lack of evolution after drop-out). All methods
mentioned are not valid under themost general missing data
mechanism, “missingness not at random” (MNAR), which
refers to the fact that, in addition to covariates and observed
outcomes, also unobserved outcomes influence the proba-
bility of missingness.10
Suissa analyzed the effects of selective discontinuation
on the rate of decline of forced expiratory volume in 1 s
(FEV1), one of the frequently used outcomes of these
studies11 in the Canadian Optimal trial.12 In this trial,
patients with the lowest FEV1 had the lowest decline and
conversely, patients with the highest FEV1 had the highest
rate of decline. Hence, excluding a large fraction of the
worst patients as occurs in the placebo group could lead to
an overestimation of the rate of decline and conversely,
excluding a smaller fraction of these patients as occurs in
the active treatment group might lead to less of an over-
estimation of the rate of decline. As a consequence, the
end-result could appear as if a treatment effect would be
present on rate of decline of FEV1,
8 whereas in reality there
is none. Similar concepts may apply to mortality and
exacerbations, which constitute other important outcomes
in COPD studies.11e16 Along these lines, evidence is present
that mortality rate is indeed high in discontinued patients.6Little information is presently available on the charac-
teristics of discontinued patients, themechanisms governing
discontinuation, andmodels predicting discontinuation from
COPD trials. Such information can be critically important and
needs to be considered when preparing an analysis plan and
when interpreting observed treatments effects. The present
manuscript is a secondary analysis from the recently pub-
lished UPLIFT (Understanding the Potential Long-Term
Impacts on Function with Tiotropium)-trial. Its purpose is:
1) to describe the pattern of drop-out as a function of time
and duration of the trial in a large 4 year trial; 2) to compare
the baseline and in trial characteristics of completers and
non-completers; 3) to construct a model predicting prema-
ture discontinuation on the basis of the functional charac-
teristics observed at baseline and during the trial.
Materials and methods
Design
The details of the study design of the UPLIFT-trial have been
reported previously.7,17,18 Briefly, the study was a 4-year,
randomized, double-blind, placebo-controlled, parallel-
group study involving patients with moderate-to-very
severe COPD. The two co-primary endpoints were the
yearly rate of decline in pre-bronchodilator and post-
bronchodilator FEV1. Secondary endpoints were lung func-
tion at each visit, health status measured with the
St. George’s Respiratory Questionnaire (SGRQ), exacerba-
tions and exacerbation-related hospitalizations, and
mortality from all causes and from lower respiratory condi-
tions. More details are provided in the on-line repository.
Patients received either 18 mg of tiotropium or
a matching placebo, once daily, delivered via the Handi-
Haler (Boehringer-Ingelheim, Germany). All concomitant
respiratory medications, except inhaled anticholinergics,
were allowed during the trial. Details on patient recruit-
ment and inclusion/exclusion criteria have been reported
previously.7,17,18 Briefly, 5993 patients were randomized to
either tiotropium (n Z 2987) or to placebo (n Z 3006).
Measurements
Spirometry was performed according to the American
Thoracic Society guidelines at randomization, at 1-month
and then every 6 months until the end of the study period.19
The details of this examination have been published
previously.7,17
Health-related quality of life was measured using the
St. George’s Respiratory Questionnaire, which was admin-
istered prior to spirometry. Exacerbations were defined as
an increase or new onset of more than one respiratory
symptom (cough, sputum, sputum purulence, wheezing, or
dyspnea) lasting for at least three days and requiring
treatment with an antibiotic, systemic steroid or both.
Safety
Adverse events were recorded at each clinic visit. Data
regarding vital status were requested for all patients who
Figure 1 Probability of completion of study drug vs. duration
of the study. Tiotropium, ( ), Control, ( ) (modified from7).
Premature discontinuation during UPLIFT 1525prematurely discontinued study drug prior to 4 years from
the first day of study drug administration. Mortality analysis
was performed both for on-treatment mortality and on-
treatment mortality þ vital status data of discontinued
patients at the end of the treatment period (day 1440) and
at the end of the 30 days follow-up period after treatment
(day 1470).7,18
Statistical analysis
Decline of pulmonary function vs. time was analyzed with
random coefficient regression in which the FEV1 changed
linearly after 30 days for each patient, intercepts and
slopes were random and the treatment effect was fixed.
The same model was used for SGRQ decline vs. time (from 6
months until completion of the study). All patients who
underwent randomization and received study drug and who
had at least three post-randomization measurements of
pulmonary function (at least two for SGRQ) were used in
the analysis.
Cox regression was used to calculate hazard ratios.
KaplaneMeier curves of the probability of no exacerbation
and consequent hospitalization were constructed.20 The
number of events and event days were compared between
the study groups with relative risks through the use of
Poisson regression with correction for overdispersion.20
A logistic regression model was constructed to predict
trial completion.20 Variables were selected stepwise from:
age, gender, race, height, weight, body-mass index (BMI),
smoking status, baseline pre-bronchodilator FEV1, post-
bronchodilator FEV1, region, baseline use of long-acting
beta-agonists (LABA), use of inhaled corticosteroids (ICS)
and SGRQ total score. Pack years was not entered in the
model because this variable is dependent on age. Variables
with p-values <0.05 were retained in the final model.
Completion was defined as completion of 45 months of
treatment and no discontinuation due to adverse event
after 45 months.
Analyses were performed with SAS software, version 8.2
(SAS Institute, Cary, North-Carolina). All reported p-values
are two-sided and not corrected for multiple testing.
Role of the funding source
The studywas supported by Boehringer-Ingelheimand Pfizer.
The design of the trial, monitoring of the conduct, review
and interpretation of the data, approval of the statistical
analyses, writing of the manuscript, and decision to publish
the manuscript involved a joint advisory committee
composed of four academics (three investigators, MD, BC, DT
and a statistician, Steph Senn), three researchers employed
by Boehringer-Ingelheim (SK, Deborah Burkhart, Shailendra
Menjoge) and a representative of Pfizer (Sunil Mehra). DL
performed the statistical analysis of the present data as an
employee of Boehringer-Ingelheim. GM was involved in the
present analysis and its interpretation, because of his
expertise in statistics withmissing data. The first draft of the
paper was written by an academic investigator (MD), and
the final content of the manuscript was developed inf Including one patient who received treatment for less than 45 montcollaboration by all authors. All authors had full access to the
data and guarantee the accuracy and completeness of the
data and the analyses. The final responsibility for the
decision to submit the manuscript was borne by the first
author (MD).
Results
Pattern of discontinuation as a function of time and
duration of the trial
In total, 5993 patients were randomized, 2987 and 3006 in
the tiotropium and placebo group, respectively. A total of
1100f patients did not complete the study in the tiotropium
group and 1358 in the control group (37 vs. 45%, p < 0.001).
The major reason for discontinuation was adverse events
(tiotropium 627 vs. placebo 746), which were mostly
worsening of COPD, followed by consent withdrawal (300
vs. 403), non-compliance with the protocol (48 vs. 75), lost
to follow-up (64 vs. 76) and others (61 vs. 58). Except for an
initial steeper decline in the retention curve, discontinua-
tion occurred in a nearly linear fashion throughout the
study, however, the slope being steeper in the placebo
group (Fig. 1).
Characteristics of completers and non-completers
The baseline characteristics of completers and non-
completers are summarized in Table 1. As can be seen
discontinuation was less frequent in GOLD stage II and more
frequent in GOLD stage III and IV (p < 0.0001). The
proportion of patients discontinued within a GOLD stage
were: 36% Stage II, 49% Stage III, 13% Stage IV. The number
of pack years smoked at baseline was greater in the non-
completers (p < 0.002). Use of major respiratory medica-
tions both at baseline and during the study was not
significantly different between completers and non-
completers, except for inhaled anticholinergics at base-
line. Pre-bronchodilator and post-bronchodilator FEV1 werehs but was reported by investigator as a completer.
Table 1 Baseline characteristics in completers and non-completers. Means  SD.
Characteristic Completers Non-completers p Completers Non-completers p
Control Control Control Tiotropium Tiotropium Tiotropium
number 1648 1358 1886 1100
% male 76 71 0.0009 76 74 0.1796
GOLD II/III/IV 54/39/5 35/50/14 <0.0001 51/42/6 39/47/13 <0.0001
Age, yrs 64  8 66  9 <0.0001 64  8 66  8 <0.0001
Ex-/Current smokers 71/29 70/30 0.558 72/28 69/31 0.156
number of packyrs 47  27 50  29 0.0023 47  27 52  29 0.0002
COPD duration,y 10  7 10  7 0.492 10  8 10  7 0.315
Baseline LABA,% 59 61 0.287 60 60 0.779
Baseline ICS, % 61 63 0.419 61 63 0.384
Baseline AC, % 41 49 <0.0001 43 50 0.0006
FEV1, pre-, L 1.18  0.40 0.99  0.38 <0.0001 1.14  0.40 1.03  0.40 <0.0001
FEV1, pre-, %pred 42  11 37  12 <0.0001 41  12 38  12 <0.0001
FEV1, post, L 1.41  0.43 1.20  0.42 <0.0001 1.38  0.43 1.24  0.44 <0.0001
FEV1, post, %pred 50  12 44  13 <0.0001 49  12 45  13 <0.0001
FVC, post, L 3.19  0.88 2.97  0.91 <0.0001 3.15  0.86 3.00  0.87 <0.0001
FVC, post, %pred 90  18 87  19 <0.0001 89  18 87  19 0.0037
SGRQ, Total 43  17 50  17 <0.0001 44  17 48  16 <0.0001
1526 M. Decramer et al.significantly greater in completers whether expressed in
liters or as a percentage of predicted (p < 0.0001 for both).
A similar difference was seen for pre- and post-
bronchodilator forced vital capacity (FVC). SRGQ total
score was significantly higher, indicating worse health-
related quality of life, in the non-completers than in the
completers (p < 0.0001). Similar differences were observed
for the three domain scores.Treatment effects in completers and non-
completers
Table 2 summarizes the treatment effects on the annual
rate of decline of pulmonary function variables and SGRQ.
Rate of decline of FEV1 was significantly higher in non-
completers than in completers. Similar differences were
seen in the rate of decline of FVC and SVC. At each point in
time during the trial including the baseline, FEV1 was
greater in the completers than in the non-completers e.g.
in control, differences ranging from 180 to 250 mL for post-
bronchodilator FEV1 (p < 0.0001). Similar differences were
seen for pre-bronchodilator FEV1, pre- and post FVC, and
pre- and post SVC.Table 2 Annual decline in FEV1, FVC, SVC and SGRQ. For the lu
unitis.year1. Means  SD.
Characteristic Completers Non-completers p
Control Control Con
Decline FEV1, pre 30 38 0.02
Decline FEV1, post 40 58 <0.
Decline FVC, pre 35 66 <0.
Decline FVC, post 53 106 <0.
Decline SVC, pre 37 71 <0.
Decline SVC, post 56 115 <0.
Decline SGRQ 1.05  0.10 2.46  0.25 p <Similarly, the annual rate of increase of the SGRQ total
score during the trial was substantially greater in non-
completers than in completers (p < 0.0001). Similar differ-
ences were seen for the three domain scores. The SGRQ total
score was lower, indicating better quality of life, in
completers than in non-completers at all points in time
during the trial, e.g. the difference in the control group
ranging from 5.9 to 10.8 units (p < 0.0001). Differences of
similar magnitude were seen for the three domain scores.
Treatment by completer status interaction did not reach
statistical significance for any of the scores. Fig. 2 summa-
rizes the SGRQ scores over time in the control and tiotropium
groups, for completers and non-completers. As can be seen
the difference between completers and non-completers
clearly increased over time, suggesting that SGRQ under
treatment was related to discontinuation as well.
Table 3 summarizes the data on exacerbations and
resulting hospitalizations in completers and non-completers
during the trial. Both in completers and non-completers,
a significant reduction in the risk of an exacerbation and
in the number of exacerbations per patient year were seen
with tiotropium (hazard ratio or HR 0.89 and 0.86, both
p < 0.01; rate ratio or RR 0.87 and 0.88, p < 0.001 and
<0.03, respectively). Time to first hospitalization wasng volumes decline is expressed in mL year1 and for SGRQ in
Completers Non-completers p
trol Tiotropium Tiotropium Tiotropium
3 29 41 0.002
0001 38 56 <0.0001
0001 38 77 <0.0001
0001 54 112 <0.0001
0001 42 88 <0.0001
0001 59 115 <0.0001
0.0001 1.04  0.9 3.04  0.26 p < 0.0001
Figure 2 Evolution of the SGRQ score vs time in tiotropium
( ) and control ( ), in completers (solid line) and non-
completers (dashed line).
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Premature discontinuation during UPLIFT 1527significantly prolonged in the tiotropium group among the
non-completers only (HR 0.85, p < 0.03), whereas the
number of hospitalizations per patient year was similar in
the control and tiotropium groups in both completers and
non-completers. For both treatment groups, the risk of an
exacerbation was significantly smaller (p < 0.0001), the
median time to first exacerbation significantly longer
(p < 0.0001) and the number of exacerbations per patient
year significantly lower (p < 0.0001) in completers than in
non-completers. The risk of a hospitalization was smaller
(p < 0.0001) and the number of hospitalizations per patient
year was significantly lower (p < 0.0001) in completers
compared with non-completers. The interaction of these
variables with completer status did not reach statistical
significance.
The number of fatalities observed on-treatment was 402
cases in the control group and 368 in the tiotropium group.
Including the vital status information up to day 1470, the
number of fatalities increased to 495 in the control group
and 439 in the tiotropium group.
Model predicting discontinuation
Odds ratios with 95% confidence limits expressing the ratio
completer/non-completer are shown in Table 4, for the
whole group of patients. The following baseline variables
were positively related to study completion: BMI, post-
bronchodilator FEV1, male gender and treatment with tio-
tropium. The following baseline variables were negatively
related to completion: age, SGRQ, female gender, current
smoking and assignment to the placebo group. Region did
not contribute significantly to the model. The model fitting,
however, was not sufficient (R2Z 0.1325) to allow accurate
prediction of drop-out.T
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pDiscussion
The present analysis of the UPLIFT study demonstrated that
the discontinuation rates were substantial (36e45%) and
significantly greater in the control group than in the active
treatment group as observed in many COPD trials before.1e8
Table 4 Odds ratio (95% CI) completer/non-completer.
Characteristic Odds ratio 95% CI p
Age 0.96 0.96e0.97 <0.0001
BMI 1.03 1.02e1.04 <0.0001
Post-BD FEV1% 1.04 1.03e1.05 <0.0001
Pre-BD FEV1% 0.99 0.98e0.99 0.037
SGRQ total 0.98 0.98e0.99 <0.001
Gender, F/M 0.83 0.73e0.95 0.007
Smoking, Current/Ex 0.75 0.66e0.86 <0.0001
Treatment C/Tio 0.69 0.62e0.78 <0.0001
1528 M. Decramer et al.Drop-out occurred in a nearly linear fashion as a function of
time. The most important common reason for discontinu-
ation was worsening of COPD. In general, patients dis-
continuing were older, had lower post-BD FEV1 and BMI,
poorer health status, more exacerbations and more pack
years of smoking and were more likely to be current
smokers and female, than patients completing the study.
Since this withdrawal rate is large and selective, it is
expected to affect the treatment effects. It is generally
believed that such a differential withdrawal rate tends to
reduce the magnitude of the treatment effects.3,6,8
Notwithstanding, Suissa recently demonstrated that in the
Canadian Optimal trial,12 patients with the lowest FEV1 had
the lowest decline and patients with the highest FEV1 had
the highest decline.11 In the present dataset, this seems to
be contradicted by the observation that discontinued
patients tended to have higher rates of decline. The latter
observation, however, needs to be interpreted with some
degree of caution as these estimates are on average based
on considerably fewer data points than in the completers.
Differential discontinuation poses a tremendous problem
for the estimation of the effect size. Greenland et al. recently
demonstrated, using the VA-exacerbation trial,21 that the
treatment effect of tiotropium on the probability of exacer-
bations was highly dependent upon the method of analysis
used.22 Indeed, even for this trial where discontinuation rates
were only 8%, there were substantial differences in the esti-
mated time to first event among the different analyses: ITT,
on-treatment, per protocol and a nested G-estimation
method. The first three conventional analyses all under-
estimated significant treatment effects. The ITT analysis
estimated the prolongation of the time to first COPD exac-
erbation to be 21%, whereas the nested G-estimation method
obtained an estimate of 31%. These differences are expected
to be larger in trials with a greater degree of discontinuation
and a longer duration such as UPLIFT.
Logistic regression analysis demonstrated that several
baseline variables were significantly related to withdrawal.
These included: age, FEV1, BMI, health status, exacerba-
tions, current smoking and gender. Although these factors
were significantly related to withdrawal, the model fitting
was not satisfactory (see above). This suggests that the
relationships between these variables and withdrawal
were e although statistically highly significant-not very
tight. As a result, these variables probably do not permit the
construction of models that will predict withdrawal precisely
and hence, it will remain difficult to adequately correct
treatment effects for the large withdrawal observed.Along these lines it appears advisable in future trials to
follow patients up who dropped-out from the trial and to
perform the scheduled examinations in these patients. This
is required to perform a valid ITT analysis.23 The present
trial also clearly demonstrated that on-treatment SGRQ
score was an important predictor of discontinuation. This
was also seen for decline in FEV1. In general, it could be
concluded that outcome variables appear to be important
predictors of discontinuation and that the latter is not only
determined by baseline variables.
The present trial also clearly demonstrated that signifi-
cant mortality occurred in patients who withdrew from the
trial and therefore, that it may not be optimal to base the
demonstration of drug effects on mortality solely on the on-
treatment population. In the present trial, the latter
strategy would have led to an 18% underestimation of
mortality rate or conversely, the true mortality rate was
21% higher than the on-treatment mortality rate, 23% in the
control group and 19% in the tiotropium group. Since
mortality has become a preferred outcome in COPD trials
now,6,8 this finding appears of great relevance for future
trials. It further also supports the need for further follow-
up of patients who withdrew from the trial as was done in
the present trial and in the TORCH-study.6 In the latter
study, considerably more mortality occurred in patients
who withdrew from the study than in the present study.
Indeed, 411 of the 875 deaths or 47% of the deaths occurred
in patients who withdrew from the study. In the UPLIFT
study only 164 deaths out of 934 or 18%, occurred in
patients who withdrew. There is no apparent explanation
for this discrepancy, although differences in respiratory
medication restrictions in each of the trials may have
contributed to the observation.
The present analysis represents one of the first detailed
analyses of the discontinuation phenomenon in a large
long-term clinical trial. Similar observations were made by
Calverley et al. with their analysis of withdrawal in the
ISOLDE study.24 They also found a lower baseline FEV1,
greater rate of decline of FEV1, and faster decline in health
status in patients withdrawing from this trial. The strengths
of the present trial include rigorous data capture, size
(5993 patients), long duration of follow-up (4 years), the
completeness of the outcomes studied (pulmonary func-
tion, health status, exacerbations, resulting hospitaliza-
tions and mortality) and the independent adjudication of
causes of death. The most relevant limitation is that except
for vital status, no follow-up was provided for the patients
who prematurely discontinued from the trial (see above).
Premature discontinuation during UPLIFT 1529As a consequence, the information available for these
patients, particularly the rate of decline data, is based on
considerably fewer data points than for the completer
population. In future trials, provision for complete follow-
up of the drop-out patients who survived to the end of
the treatment period would provide us with considerably
more complete information on these patients. However, it
is recognized that following patients after discontinuation
of study medication is logistically and ethically challenging.
The latter would be the case with a patient who would
refuse all further follow-up after withdrawal. A compro-
mise that might be considered could be that at least follow-
up data would be obtained at the end of the anticipated
treatment period in all patients.
In conclusion, in the present large scale clinical trial
discontinuation rates were substantial and, greater in the
placebo group than in the active treatment group. Discon-
tinuation occurred in a nearly linear fashion. The prime
baseline factors associated with a greater probability of
discontinuation were older age, lower FEV1, lower BMI,
poorer health status, current smoking and female gender.
On-treatment variables were important determinants of
discontinuation as well. It therefore appears advisable that
longer term clinical trials consider follow-up of patients
who prematurely discontinue trial participation.
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